标题
Advances in biological therapies for dyslipidemias and atherosclerosis
作者
关键词
Monoclonal antibodies (mAbs), Vaccines, Immunotherapy, Antisense oligonucleotides (ASOs), Genome/base editing, Gene therapy, Precision medicine
出版物
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 116, Issue -, Pages 154461
出版商
Elsevier BV
发表日期
2020-12-05
DOI
10.1016/j.metabol.2020.154461
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The promise and challenge of therapeutic genome editing
- (2020) Jennifer A. Doudna NATURE
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo
- (2020) Liu Yang et al. Molecular Therapy-Nucleic Acids
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bioconjugated oligonucleotides: recent developments and therapeutic applications
- (2019) sebastien benizri et al. BIOCONJUGATE CHEMISTRY
- In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
- (2019) Alba Carreras et al. BMC BIOLOGY
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Application of PCSK9 Inhibitors in Practice
- (2019) Tina M. Kaufman et al. CIRCULATION RESEARCH
- Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
- (2019) Michael B. Boffa et al. Nature Reviews Cardiology
- Adeno-associated virus vector as a platform for gene therapy delivery
- (2019) Dan Wang et al. NATURE REVIEWS DRUG DISCOVERY
- Anticytokine Agents
- (2019) Paul M Ridker CIRCULATION RESEARCH
- Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art
- (2019) Fatemeh Vahdat Lasemi et al. DRUG DISCOVERY TODAY
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- The next generation of CRISPR–Cas technologies and applications
- (2019) Adrian Pickar-Oliver et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Triple-Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases
- (2019) Lingmin Zhang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease
- (2019) Eftaxia-Konstantina Valanti et al. CURRENT OPINION IN LIPIDOLOGY
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia
- (2019) Huan Zhao et al. CIRCULATION
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
- (2019) Erin D. Michos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduction of myocardial ischaemia–reperfusion injury by inactivating oxidized phospholipids
- (2018) Calvin Yeang et al. CARDIOVASCULAR RESEARCH
- Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
- (2018) Alexandra C. Chadwick et al. CIRCULATION
- Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
- (2018) Emelia J. Benjamin et al. CIRCULATION
- Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
- (2018) Eswar Kandaswamy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway
- (2018) Dimitris Theofilatos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dyslipidaemia: In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
- (2018) June-Wha Rhee et al. Nature Reviews Cardiology
- Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – Novel insights and future directions in diagnosis and therapy ,
- (2018) Adam Hartley et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
- (2018) Xuchu Que et al. NATURE
- CRISPR-Cas guides the future of genetic engineering
- (2018) Gavin J. Knott et al. SCIENCE
- IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3)
- (2018) Victor J. van den Berg et al. EBioMedicine
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
- (2018) Laurens F. Reeskamp et al. ATHEROSCLEROSIS
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Base editing: precision chemistry on the genome and transcriptome of living cells
- (2018) Holly A. Rees et al. NATURE REVIEWS GENETICS
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
- (2017) Wolfgang Poller et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability
- (2017) Daniel B. Mark et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
- (2017) Carl E. Orringer et al. Journal of Clinical Lipidology
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
- (2017) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- After Glybera's withdrawal, what's next for gene therapy?
- (2017) Melanie Senior NATURE BIOTECHNOLOGY
- A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels
- (2017) Sumeet A Khetarpal et al. NATURE MEDICINE
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Antisense Oligonucleotides
- (2017) Stanley T. Crooke Nucleic Acid Therapeutics
- Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
- (2017) Beatrice Oehler et al. Scientific Reports
- Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia
- (2017) Jenny A. Greig et al. Human Gene Therapy Clinical Development
- Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR+/− Rhesus Macaques
- (2017) Jenny A. Greig et al. Human Gene Therapy Clinical Development
- Familial hypercholesterolaemia
- (2017) Joep C. Defesche et al. Nature Reviews Disease Primers
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
- (2017) Ann Marie Navar et al. JAMA Cardiology
- Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits
- (2017) Bradley K. Wacker et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease
- (2017) Kelsey E. Jarrett et al. Scientific Reports
- Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE)
- (2016) Shu Ren et al. AMERICAN HEART JOURNAL
- Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of AtherosclerosisHighlights
- (2016) Bradley K. Wacker et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary EventsSignificance
- (2016) Harry Björkbacka et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis
- (2016) Shin-ya Morita BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
- (2016) Ola Kleveland et al. EUROPEAN HEART JOURNAL
- Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
- (2016) Alan Chait et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Genome editing in cardiovascular diseases
- (2016) Alanna Strong et al. Nature Reviews Cardiology
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
- (2016) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients
- (2016) Tong Shen et al. PHARMACEUTICAL RESEARCH
- Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes
- (2016) Giuseppe Asciutto et al. STROKE
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis
- (2015) Luke J Leman Clinical Lipidology
- Acute myocardial infarction and influenza: a meta-analysis of case–control studies
- (2015) Michelle Barnes et al. HEART
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
- (2015) Viktoria Gusarova et al. JOURNAL OF LIPID RESEARCH
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- In vivo genome editing using Staphylococcus aureus Cas9
- (2015) F. Ann Ran et al. NATURE
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III: From Pathophysiology to Pharmacology
- (2015) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
- (2015) Joshua Lehrer-Graiwer et al. JACC-Cardiovascular Imaging
- HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
- (2015) Kuang-Yuh Chyu et al. Frontiers in Pharmacology
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
- (2014) Amit C. Nathwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia
- (2012) Sadik H. Kassim et al. HUMAN GENE THERAPY
- Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions
- (2012) Rogier A. van Dijk et al. JOURNAL OF LIPID RESEARCH
- Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
- (2012) Tsuyoshi Yamamoto et al. Molecular Therapy-Nucleic Acids
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
- (2011) Esther Merki et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Expression of Apolipoprotein A-I in Rabbit Carotid Endothelium Protects Against Atherosclerosis
- (2011) Rowan Flynn et al. MOLECULAR THERAPY
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
- (2011) Amit C. Nathwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study
- (2010) Aldar S Bourinbaiar et al. Lipids in Health and Disease
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Gene Therapy in a Humanized Mouse Model of Familial Hypercholesterolemia Leads to Marked Regression of Atherosclerosis
- (2010) Sadik H. Kassim et al. PLoS One
- Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study
- (2008) A. Ciszewski et al. EUROPEAN HEART JOURNAL
- High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction
- (2008) P. Sjogren et al. EUROPEAN HEART JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More